Information Library
Results for: Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
DIA China
Event — Conference Date(s): May 20 - May 23, 2012
Location: Shanghai, China
-
Quintiles Forms New Biomarker Research and Development Company
Press Release — January 18, 2012 – Quintiles announced that it has invested in a new company formed to provide oncology consulting services and new cancer biomarkers, the key to scientific selection of the right drug for the right patient.
-
DIA US 2012
Event — Conference Date(s): June 24 - June 28, 2012
Location: Philadelphia, PA Pennsylvania Convention Center
Booth Number: 1401
-
ASCO 2012
Event — Conference Date(s): June 1 - June 5, 2012
Location: Chicago, IL McCormick Place
Booth Number: 2062
-
BioPharma Asia 2012
Event — Conference Date(s): March 19 - March 22, 2012
Location: Singapore Marina Bay Sands
-
Intarcia and Quintiles Finalize Innovative Alliance
Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).
-
Quintiles Launches China CRO, Kun Tuo
Press Release — December 13, 2011 – Further deepening its commitment to China, Quintiles announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.
-
Quintiles Names New Global Head of Clinical & Data Operations
Press Release — October 6, 2011 – Quintiles announced that Steven Skolsky has been appointed Global Head of its Clinical & Data Operations (CDO) unit.
-
Energizing Enrollment
Case Study — October 4, 2011
The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned. -
Partnering is Key to Maximizing Rewards in Emerging Markets
Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.
